Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Bullish +75

Aflac Earnings Call Highlights Japan Surge and Strength

AI-generated analysis

πŸ“ˆ Aflac reported Q1 adjusted earnings per diluted share of $1.75, representing roughly 6.6% year-over-year growth.

πŸ‡―πŸ‡΅ Japan sales surged 25.5% in the first quarter driven by new products like Onsen Tallett and the Miraito cancer line.

πŸ’° Adjusted return on equity remained strong at 12.8% company-wide, with Japan's pretax margin climbing to 35%.

πŸ‡ΊπŸ‡Έ U.S. sales increased 2.9% while net earned premium grew 3.5%, supported by a premium persistency rate of 79.3%.

πŸ’΅ The company returned approximately $1.3 billion to shareholders through share repurchases and dividends in the quarter.

🏦 Aflac holds $3.4 billion of unencumbered liquidity, which is roughly $2.4 billion above its internal minimum threshold.

πŸ”„ Strategic progress was made at Aflac Re Bermuda after assuming a block from Japan Post Insurance for diversification.

πŸ“‰ Despite strong new sales, Japan's net earned premiums fell 3.8% in yen terms due to lapses and policy migrations.

⚠️ Reserve remeasurement gains contributed significantly to reported results but are considered nonrecurring and timing-related.

🏒 The Corporate & Other segment slipped to breakeven pretax adjusted earnings from a $43 million gain the prior year.

πŸ“‰ Credit and real estate investments faced pressure with $19 million in loan charge-offs and $24 million in real estate impairments.

πŸ“ˆ U.S. group products grew about 12.4% for the quarter as initiatives improved agent onboarding and productivity.

🎯 Management reaffirmed full-year guidance for Japan's benefit ratio between 60% and 63%.

πŸ“‰ The U.S. expense ratio rose to 38.3%, driven by higher DAC amortization and commissions.

πŸ“‰ An external reinsurance transaction in Japan modestly reduced earnings, expected to turn neutral over the next few quarters.

πŸ“‰ Corporate & Other earnings are sensitive to short-term interest rates, with expectations of slightly negative pretax earnings in Q2.

Bullish Signals
  • Aflac Japan delivered a 25.5% jump in first-quarter sales, driven by new products like the Onsen Tallett medical product and the Miraito cancer line.
  • Adjusted earnings per diluted share rose to $1.75, representing about 6.6% growth year over year, with favorable reserve remeasurement gains of $82 million adding roughly $0.04 per share.
  • In the U.S., sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention as premium persistency reached 79.3%.
  • Company-wide profitability remained compelling with adjusted return on equity at 12.8%, and Japan's pretax margin climbed to 35%, up 320 basis points.
  • Aflac underscored a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum.
  • The company returned about $1.3 billion to shareholders in the quarter through share repurchases and dividends, extending its multi-decade dividend growth streak.
  • Japan's total benefit ratio improved to 62.9%, a 290-basis-point year-over-year decline, aided by favorable claims experience.
  • The U.S. group segment continued to gain traction with group products up about 12.4% for the quarter and targeted mix growth of roughly 25%.
  • Management reaffirmed full-year guidance for Japan's benefit ratio at 60%-63% and the U.S. at 42%-52%, signaling confidence in maintaining disciplined underwriting.
  • Aflac plans to keep adjusted leverage within its 20%-25% corridor and continue tactical capital deployment to support shareholder returns.
Risk Factors
  • Favorable reserve remeasurement gains of $82 million added roughly $0.04 per share, but executives cautioned these items are partly timing-related and nonrecurring, meaning some favorable claims experience may not repeat in future quarters.
  • Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned, reflecting continued weakness in commercial real estate markets.
  • U.S. statutory impairments totaled $12 million, accompanied by a small mortgage loan valuation allowance and variable investment income that ran about $14 million below long-term expectations.
  • The U.S. expense ratio rose to 38.3%, up 70 basis points year over year, driven by higher DAC amortization and commissions, which compressed margin expansion in the near term.
  • An external reinsurance transaction ceding first-sector business modestly reduced Aflac Japan earnings by a mid-single-digit U.S. dollar amount in the quarter, with management expecting it to be slightly negative to earnings for the next few quarters before turning neutral.
  • Achieving flat earned premium in Japan would require about JPY 90 billion of annual sales, compared with roughly JPY 74 billion generated in 2025, signaling that further execution gains are needed to fully offset policy lapses and paid-up movements.
Full Analysis
Aflac Incorporated reported first-quarter earnings driven by strong new business momentum in Japan, where sales surged 25.5% fueled by new products like the Onsen Tallett medical line and the Miraito cancer line. Adjusted earnings per diluted share rose to $1.75, or approximately $1.77 excluding foreign-exchange effects, representing about 6.6% year-over-year growth. This performance was aided by favorable reserve remeasurement gains of $82 million, which added roughly $0.04 per share and helped lift results above internal plans. In the United States, sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention with premium persistency reaching 79.3%. Group voluntary products showed particular strength, helping stabilize and expand the U.S. franchise, with group segment growth of about 12.4% for the quarter. Company-wide profitability remained compelling, with adjusted return on equity at 12.8%, while Japan's pretax margin climbed to 35% and the U.S. business held a solid pretax margin of 20.4%. The company maintained a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum, and adjusted leverage of 21.2% within its target range. Aflac returned about $1.3 billion to shareholders through share repurchases and dividends, extending its multi-decade dividend growth streak. Strategic progress was noted at Aflac Re Bermuda, which assumed a block from Japan Post Insurance, positioning reinsurance as a future growth engine. However, challenges included softer earned premiums in Japan due to lapses and paid-up policy migrations, with net earned premiums falling 3.8% in yen terms despite new sales. The Corporate & Other segment slipped to roughly breakeven pretax adjusted earnings from a $43 million gain a year earlier due to lower investment income and higher interest expense. Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned, reflecting continued weakness in commercial real estate markets. Management reaffirmed full-year guidance for Japan's benefit ratio at 60%–63% and the U.S. at 42%–52%, signaling confidence in maintaining disciplined underwriting. The company plans to keep adjusted leverage within its 20%–25% corridor and expects Japan sales to be roughly in line with 2025 levels, while aspiring to higher volumes to stabilize earned-premium growth over time. Executives cautioned that reserve remeasurement gains are partly timing-related and nonrecurring, meaning some favorable claims experience may not repeat in future quarters.